Trial
NCT06065059
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Tango Therapeutics, Inc.
Collaborators
—
Condition
Breast Cancer
Intervention
TNG348
Why stopped
Terminated due to safety
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-13